Third Wave Technologies Launches Analyte Specific Reagents for A1298C Mutation in the MTHFR Gene

Mutation Associated With Deep Vein Thrombosis



Apr 05, 2001, 01:00 ET from Third Wave Technologies, Inc.

    MADISON, Wis., April 5 /PRNewswire/ --
 Third Wave Technologies, Inc. (Nasdaq: TWTI) today announced the launch of a
 new set of analyte specific reagents based upon its Invader(R) operating
 system.  This reagent set is specific for the A1298C mutation in the methylene
 tetrahydrofolate reductase (MTHFR) gene.  Third Wave previously released a
 reagent set specific for the C677T mutation in the MTHFR gene.  These
 mutations have been associated with hyperhomocystinemia and linked to the
 development of deep vein thrombosis (DVT).  This is the fourth set of analyte
 specific reagents and controls that Third Wave is selling for routine clinical
 use based on its proprietary Invader operating system.
     It has been shown that together with the C677T mutation, the A1298C
 mutation indicates an increased risk of DVT.  The presence of these mutations
 in the MTHFR gene interferes with the normal activity of a key enzyme involved
 in converting homocystine to methionine, resulting in elevated levels of
 homocystine which increases the chances for DVT and other life-threatening
 conditions of the cardiovascular system.  The availability of these new
 reagents adds an important new tool for physicians treating patients who may
 be at risk for developing blood clots.
     "The launch of this additional MTHFR reagent set is the first of several
 new offerings we plan to introduce for routine clinical use this year based on
 our Invader operating system," said Lance Fors, Ph.D., President and CEO of
 Third Wave.  "We continue the successful implementation of our business plan
 which includes designing and producing products for the research market, and
 transferring those analyte-specific reagents that have been shown to be
 predictors of disease to the clinical laboratory setting."
     "These additional Invader reagents for detecting the A1298C mutation in
 the MTHFR gene will be an important addition to our screening panel," said
 William Luper, M.D., Director of Hemostasis and Thrombosis Laboratories,
 Springbranch Medical Center, Houston, Texas.  "Invader technology-based assays
 are easier to run, require less lab space and equipment and are proving to be
 significantly less expensive than PCR-based tests."
 
     Third Wave Technologies is a leading provider of products for analyzing
 genetic variations.  The Company's patented genetic analysis platform, the
 Invader operating system, offers several advantages over conventional genetic
 analysis technologies.  Third Wave's products produce highly accurate results,
 are easy to use and eliminate the need for making multiple copies of the
 genetic sample, saving the user time and money while significantly reducing
 the risks associated with sample contamination.  Additionally, the Invader
 products are compatible with existing automation processes and detection
 platforms and are available in convenient, ready-to-use formats.  These
 advantages make Third Wave's products ideally suited for large-scale genetic
 analysis for both research and clinical applications, including drug discovery
 and development and patient diagnosis and treatment.  Third Wave's proprietary
 products and technologies position us to exploit the growing market
 opportunity for genetic analysis products.
 
     All statements in this press release that are not historical are
 forward-looking statements within the meaning of the Securities Exchange Act
 of 1934 as amended.  Such forward-looking statements are subject to factors
 that could cause actual results to differ materially for Third Wave from those
 projected.  Those factors include risks and uncertainties relating to
 technological approaches of Third Wave and its competitors, product
 development, manufacturing, market acceptance, cost and pricing of Third Wave
 products, dependence on collaborative partners and commercial customers,
 successful performance under collaborative and commercial agreements,
 competition, the strength of the Third Wave intellectual property, the
 intellectual property of others and other risk factors identified in the Third
 Wave prospectus filed with the Securities and Exchange Commission on
 February 9, 2001, as well as other documents which Third Wave will, from time
 to time, file with the SEC.  Copies of the Third Wave filings with the SEC may
 be obtained from the SEC internet site at http://www.sec.gov.
 
 

SOURCE Third Wave Technologies, Inc.
    MADISON, Wis., April 5 /PRNewswire/ --
 Third Wave Technologies, Inc. (Nasdaq: TWTI) today announced the launch of a
 new set of analyte specific reagents based upon its Invader(R) operating
 system.  This reagent set is specific for the A1298C mutation in the methylene
 tetrahydrofolate reductase (MTHFR) gene.  Third Wave previously released a
 reagent set specific for the C677T mutation in the MTHFR gene.  These
 mutations have been associated with hyperhomocystinemia and linked to the
 development of deep vein thrombosis (DVT).  This is the fourth set of analyte
 specific reagents and controls that Third Wave is selling for routine clinical
 use based on its proprietary Invader operating system.
     It has been shown that together with the C677T mutation, the A1298C
 mutation indicates an increased risk of DVT.  The presence of these mutations
 in the MTHFR gene interferes with the normal activity of a key enzyme involved
 in converting homocystine to methionine, resulting in elevated levels of
 homocystine which increases the chances for DVT and other life-threatening
 conditions of the cardiovascular system.  The availability of these new
 reagents adds an important new tool for physicians treating patients who may
 be at risk for developing blood clots.
     "The launch of this additional MTHFR reagent set is the first of several
 new offerings we plan to introduce for routine clinical use this year based on
 our Invader operating system," said Lance Fors, Ph.D., President and CEO of
 Third Wave.  "We continue the successful implementation of our business plan
 which includes designing and producing products for the research market, and
 transferring those analyte-specific reagents that have been shown to be
 predictors of disease to the clinical laboratory setting."
     "These additional Invader reagents for detecting the A1298C mutation in
 the MTHFR gene will be an important addition to our screening panel," said
 William Luper, M.D., Director of Hemostasis and Thrombosis Laboratories,
 Springbranch Medical Center, Houston, Texas.  "Invader technology-based assays
 are easier to run, require less lab space and equipment and are proving to be
 significantly less expensive than PCR-based tests."
 
     Third Wave Technologies is a leading provider of products for analyzing
 genetic variations.  The Company's patented genetic analysis platform, the
 Invader operating system, offers several advantages over conventional genetic
 analysis technologies.  Third Wave's products produce highly accurate results,
 are easy to use and eliminate the need for making multiple copies of the
 genetic sample, saving the user time and money while significantly reducing
 the risks associated with sample contamination.  Additionally, the Invader
 products are compatible with existing automation processes and detection
 platforms and are available in convenient, ready-to-use formats.  These
 advantages make Third Wave's products ideally suited for large-scale genetic
 analysis for both research and clinical applications, including drug discovery
 and development and patient diagnosis and treatment.  Third Wave's proprietary
 products and technologies position us to exploit the growing market
 opportunity for genetic analysis products.
 
     All statements in this press release that are not historical are
 forward-looking statements within the meaning of the Securities Exchange Act
 of 1934 as amended.  Such forward-looking statements are subject to factors
 that could cause actual results to differ materially for Third Wave from those
 projected.  Those factors include risks and uncertainties relating to
 technological approaches of Third Wave and its competitors, product
 development, manufacturing, market acceptance, cost and pricing of Third Wave
 products, dependence on collaborative partners and commercial customers,
 successful performance under collaborative and commercial agreements,
 competition, the strength of the Third Wave intellectual property, the
 intellectual property of others and other risk factors identified in the Third
 Wave prospectus filed with the Securities and Exchange Commission on
 February 9, 2001, as well as other documents which Third Wave will, from time
 to time, file with the SEC.  Copies of the Third Wave filings with the SEC may
 be obtained from the SEC internet site at http://www.sec.gov.
 
 SOURCE  Third Wave Technologies, Inc.